

References

S-275

1. Parsons JK, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. 2020.
2. Sundaram D, Sankaran PK, Raghunath G, et al. Correlation of prostate gland size and uroflowmetry in patients with lower urinary tract symptoms. *J Clin Diagn Res.* 2017;11(5):AC01-AC04.
3. Tanneru K, Gautam S, Norez D, et al. Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. *Int Urol Nephrol.* 2020;52(6):999-1008.
4. Sievert KD, Schonthaler M, Berges R, et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: A multicenter German evaluation after 2 years. *World J Urol.* 2019;37(7):1353-1360.
5. Jung JH, Reddy B, McCutcheon KA, Borofsky M, Narayan V, Kim MH, Dahm P. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database Syst Rev.* 2019;25;5(5):CD012832.
6. Gratzke C, Barber N, Speakman MJ, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. *BJU Int.* 2017;119(5):767-775.
7. Miller LE, Chughtai B, Dornbier RA, McVary KT. Surgical reintervention rate after prostatic urethral lift: Systematic review and meta-analysis involving over 2,000 patients. *J Urol.* 2020;204(5):1019-1026.
8. Roehrborn CG, Barkin J, Gange SN et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. *Can J Urol.* 2017;24(3):8802-8813.
9. Rukstalis D, Grier D, Stroup SP, et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12-month results of the MedLift Study. *Prostate Cancer Prostatic Dis.* 2019;22(3):411-419.

10. Shah BB, Tayon K, Madiraju S, Carrion RE, Perito P. Prostatic urethral lift: Does size matter? *J Endouro* 2018;32(7):635-638.
11. Eure G, Gange S, Walter P, et al. Real-world evidence of prostatic urethral lift confirms pivotal clinical study results: 2-year outcomes of a retrospective multicenter study. *J Endourol*. 2019;33(7):576-584.
12. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin*. 2017;67(1):7-30.
13. National Institute for Health and Care Excellence (NICE). Prostate cancer: Diagnosis and management. [NG131]. 2019.
14. Westwood J, Geraghty R, Jones P, et al. Rezūm: A new transurethral water vapour therapy for benign prostatic hyperplasia. *Ther Adv Urol*. 2018;10(11):327-333.
15. McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled rezūm system study: Convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. 2018;111:1-9.
16. Kang TW, Jung JH, Hwang EC, et al. Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database Syst Rev*. 2020;25;3(3):CD013251.
17. McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. *Urology*. 2019;126:171-179.
18. Hayes, Inc. Health Technology Assessment. *Prostatic Urethral lift (UroLift System) for Treatment of Symptoms Associated with Benign Prostatic Hyperplasia*. Lansdale, PA: Hayes, Inc.; 06/09/2020.
19. Hayes, Inc. Comparative Effectiveness Review. *Comparative Effectiveness Review of Cryoablation for Primary Treatment of Localized Prostate Cancer*. Lansdale, PA: Hayes, Inc.; 07/27/2017.
20. Hayes, Inc. Health Technology Assessment. *High-Intensity Focused Ultrasound for Salvage Therapy of Recurrent Prostate Cancer*. Lansdale, PA: Hayes, Inc.; 03/30/2017.

21. Mai, Z Xiao Y, Yan W, et al. Comparison of lesions detected and undetected by template-guided transperineal saturation prostate biopsy. *BJU Int.* 2018;121:415-420.
22. Zhang F, Shao Q, Du Y, Tian Y. Evaluation of 24-core coaxial needle saturation biopsy of the prostate by the transperineal approach in detecting prostate cancer in patients without previous biopsy history: A single center reports. *J Can Res Ther.* 2019;15:380-5.
23. Xue J, Qin Z, Cai H, et al. Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: A meta-analysis and trial sequential analysis. *Oncotarget.* 2017;8(14):23322-23336.
24. S. Preventive Services Task Force (USPSTF). Final Recommendation Statement: Prostate Cancer: Screening. 2018.
25. Hayes, Inc. Hayes Evidence Analysis Research Brief. *Transperineal Template Biopsy for Detection of Prostate Cancer in Patients with Previous Negative Transrectal Biopsy.* Lansdale, PA: Hayes, Inc.; 10/31/2019.
26. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. v.3.2022.
27. Nakai Y, Tanaka N, Anai S, et al. Transperineal template-guided saturation biopsy aimed at sampling one core for each millimeter of prostate volume: 103 Cases requiring repeat prostate biopsy. *BMC Urol.* 2017;17(28).
28. Liu G, Yan T. Pelvic phased-array mpMRI versus saturation biopsy: A diagnostic performance analysis in men with suspected advanced prostate cancer. *Scand J Urol.* 2020;54(1):14-19.
29. Amin A, Scheltema MJ, Shnier R, et al. The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies. *J Urol.* 2020;203(5):910-917.
30. Pepe P, Pennisi M, Fraggetta F. How many cores should be obtained during saturation biopsy in the era of multiparametric magnetic resonance? Experience in 875 patients submitted to repeat prostate biopsy. *Urology.* 2020;137:133-137.

31. Sanda MG, Chen RC, Crispino T, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. 2017.
32. Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: Final results of a phase III trial. *Int J Radiat Oncol Biol Phys*. 2017;97(5):976-985.
33. Schörghofer A, Drerup M, Kunit T, et al. Rectum-spacer related acute toxicity - endoscopy results of 403 prostate cancer patients after implantation of gel or balloon spacers. *Rad Oncol (London, England)*. 2019;14(1):47.
34. Hayes Health Technology Brief. *Absorbable Perirectal Spacer (Spaceoar System; Augmenix inc.) During Radiation Therapy for Prostate Cancer*. Lansdale, PA: Hayes, Inc; 4/10/2021.
35. National Institute for Health and Care Excellence (NICE). Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. NICE Interventional Procedure Guidance No. 590. London, UK: National Institute for Health and Care Excellence; 2017.
36. Fischer-Valuck BW, Chundury A, Gay H, Bosch W, Michalski J. Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall. *Pract Radiat Oncol*. 2017;7(3):195-202.
37. Miller LE, Efstathiou JA, Bhattacharyya SK, Payne HA, Woodward E, Pinkawa M. Association of the placement of a perirectal hydrogel spacer with the clinical outcomes of men receiving radiotherapy for prostate cancer: A systematic review and meta-analysis. *JAMA Netw Open*. 2020;1;3(6):e208221.
38. Te Velde BL, Westhuyzen J, Awad N, Wood M, Shakespeare TP. Can a perirectal hydrogel spaceOAR programme for prostate cancer intensity-modulated radiotherapy be successfully implemented in a regional setting? *J Med Imaging Rad Oncol*. 2017;61(4):528-533.
39. Lerner LB, McVary, KT, Barry MJ et al: Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline part I, initial work-up and medical management. *J Urol*. 2021;206:806.

40. Lerner LB, McVary, KT, Barry MJ et al: Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline part II, surgical evaluation and treatment . *J Urol*. 2021;206:818.
41. Page T, Veeratterapillay R, Keltie K, Burn J, Sims A. Prostatic urethral lift (UroLift): A real-world analysis of outcomes using hospital episodes statistics. *BMC Urol*. 2021;21(1):55.
42. National Institute for Health and Care Excellence (NICE). UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia [MTG58]. 2021.
43. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-Year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Urol*. 2021;206(3):715-724.
44. Gilling P, Barber N, Bidair M, et al. Three-year outcomes after aquablation therapy compared to TURP: Results from a blinded randomized trial. *Can J Urol*. 2020;27(1):10072-10079.
45. Hwang EC, Jung JH, Borofsky M, Kim MH, Dahm P. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database Syst Rev*. 2019;2(2):CD013143.
46. National Institute for Health and Care Excellence. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2020.
47. National Institute for Health and Care Excellence. Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. 2018.
48. Chin JL, Lavi A, Metcalfe MJ, et al. Long-term outcomes of whole gland salvage cryotherapy for locally recurrent prostate cancer following radiation therapy: A combined analysis of two centers. *J Urol*. 2021;206(3):646-654.
49. Azzouzi AR, Vincendeau S, Barret E, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): An open-label, phase 3, randomised controlled trial. *Lancet Oncol*. 2017;18(2):181-191.
50. Bates AS, Ayers J, Kostakopoulos N, et al. A Systematic review of focal ablative therapy for clinically localised prostate cancer in comparison with

standard management options: Limitations of the available evidence and recommendations for clinical practice and further research. *Eur Urol Oncol*. 2021;4(3):405-423.

51. Mehralivand S, George AK, Hoang AN, et al. MRI-guided focal laser ablation of prostate cancer: A prospective single-arm, single-center trial with 3 years of follow-up. *Diagn Interv Radiol*. 2021;27(3):394-400.
52. Chao B, Lepor H. 5-Year Outcomes following focal laser ablation of prostate cancer. *Urology*. 2021;155:124-129.
53. Nahar B, Bhat A, Reis IM, et al. Prospective evaluation of focal high intensity focused ultrasound for localized prostate cancer. *J Urol*. 2020;204(3):483-489.
54. Babar M, Katz A, Ciatto M. Dosimetric and clinical outcomes of SpaceOAR in men undergoing external beam radiation therapy for localized prostate cancer: A systematic review. *J Med Imaging Radiat Oncol*. 2021;65(3):384-397.
55. Pinkawa M, Berneking V, König L, Frank D, Bretgeld M, Eble MJ. Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer. *Strahlenther Onkol*. 2017;193(1):22-28.
56. Te Velde BL, Westhuyzen J, Awad N, Wood M, Shakespeare TP. Late toxicities of prostate cancer radiotherapy with and without hydrogel SpaceAOR insertion. *J Med Imaging Radiat Oncol*. 2019;63(6):836-841.
57. Seymour ZA, Hamstra DA, Daignault-Newton S, et al. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: A pooled prospective evaluation of bowel-associated quality of life. *BJU Int*. 2020;126(3):367-372.
58. Chao M, Ow D, Ho H, et al. Improving rectal dosimetry for patients with intermediate and high-risk prostate cancer undergoing combined high-dose-rate brachytherapy and external beam radiotherapy with hydrogel spacer. *J Contemp Brachytherapy*. 2019;11(1):8-13.
59. Kahn J, Dahman B, McLaughlin C, et al. Rectal spacing, prostate coverage, and periprocedural outcomes after hydrogel spacer injection during low-dose-rate brachytherapy implantation. *Brachytherapy*. 2020;19(2):228-233.
60. Nehlsen AD, Sindhu KK, Moshier E, Sfakianos JP, Stock RG. The impact of a rectal hydrogel spacer on dosimetric and toxicity outcomes among patients

undergoing combination therapy with external beam radiotherapy and low-dose-rate brachytherapy. *Brachytherapy*. 2021;20(2):296-301.

61. Butler WM, Kurko BS, Scholl WJ, Merrick GS. Effect of the timing of hydrogel spacer placement on prostate and rectal dosimetry of low-dose-rate brachytherapy implants. *J Contemp Brachytherapy*. 2021;13(2):145-151.